FDA rejects new ulcer-prevention use for Nexium

AstraZeneca's (NYSE: AZN) drive to broaden use of Nexium hit a snag when the FDA issued a complete response letter for its application to market the acid-reflux drug to prevent peptic ulcers associated with low-dose aspirin use. Story | Report